Abstract
In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) In a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, we were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.
Publication types
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adult
-
Aged
-
Bone Marrow / drug effects
-
Cisplatin / administration & dosage*
-
Cisplatin / adverse effects
-
Cyclophosphamide / administration & dosage*
-
Cyclophosphamide / adverse effects
-
Doxorubicin / administration & dosage*
-
Doxorubicin / adverse effects
-
Drug Therapy, Combination
-
Etoposide / administration & dosage*
-
Etoposide / adverse effects
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Neoplasm Metastasis
-
Podophyllotoxin / analogs & derivatives*
-
Remission, Spontaneous
-
Time Factors
-
Vomiting / chemically induced
Substances
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Podophyllotoxin
-
Cisplatin